Amid promising developments in the pharmaceutical industry, the antibody, administered at repeated doses of up to 8 mg/kg, demonstrated overall good tolerability. The pharmacokinetic characteristics of BTT-1023 in psoriasis patients aligned with the findings from a previous study involving rheumatoid arthritis patients, indicating a potential positive trajectory for treatment outcomes.